AF
AIM

Advisornet Financial’s AIM ImmunoTech AIM Stock Holding History

Advisornet Financial’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed -$186 – 2294
2024
Q2 		$186 Hold
5
– – ﹤0.01% 2042
2024
Q1 		$236 Hold
5
– – ﹤0.01% 1958
2023
Q4 		$220 Hold
5
– – ﹤0.01% 2279
2023
Q3 		$228 Buy
+5
New +$308 ﹤0.01% 2120

Other funds holding AIM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisornet Financial's AIM Position: Q3 2024 in Review

Advisornet Financial sold out of AIM ImmunoTech (AIM) in Q3 2024, closing a stake of 5 shares — an estimated $186 sold.

Advisornet Financial first reported a position in AIM in Q3 2023 and held it in 4 quarters. The position peaked at $236 in Q1 2024. 30 funds tracked by Wall St. Rank hold AIM as of Q3 2024.

  • Advisornet Financial reported no remaining AIM ImmunoTech position as of Q3 2024 after selling out during the quarter.
  • Advisornet Financial sold 5 AIM ImmunoTech shares in Q3 2024, an estimated $186.
  • Advisornet Financial first reported a position in AIM ImmunoTech in Q3 2023 and held it in 4 quarters.
  • Advisornet Financial's AIM ImmunoTech position peaked at $236 in Q1 2024.
  • 30 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2024.

Based on Advisornet Financial's 13F filing for Q3 2024, filed 15 Oct 2024.